drugset
drugset / Trial / NCT01981811

Adherence to Treatment, Safety and Tolerability Study of the Medical Information Device #1 (MIND1) in Subjects With Schizophrenia or Bipolar I Disorder

NCT01981811 ↗

Phase 2 Withdrawn Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate adherence to treatment with, and safety and tolerability of, the medical information device #1 (MIND1) system in subjects with Schizophrenia or Bipolar I Disorder who are currently treated with oral aripiprazole.

Timeline

Start
2014-03
Primary completion
2014-05
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified 10 mg Oral
Comparator Aripiprazole Other / unclassified 15 mg Oral
Comparator Aripiprazole Other / unclassified 20 mg Oral
Comparator Aripiprazole Other / unclassified 30 mg Oral

Indications

bipolar I disorder schizophrenia